E. Ferrannini

Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 43:31–39

M. Matsuda, Y. Miyazaki, R. DeFronzo, 2004, Diabetologia.

Beta cell function and its relation to insulin action in humans: a critical appraisal

A. Mari, E. Ferrannini, A. Mari, 2004, Diabetologia.

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

M. Matsuda, Y. Miyazaki, R. DeFronzo, 2003, Diabetologia.

A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

E. Ferrannini, H. Woerle, S. Hantel, 2013, Diabetes, obesity & metabolism.

Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome

S. Haffner, B. Mitchell, E. Ferrannini, 1991, Diabetologia.

High Serum Levels of CXC (CXCL10) and CC (CCL2) Chemokines in Untreated Essential Hypertension

S. Taddei, L. Ghiadoni, E. Ferrannini, 2012, International journal of immunopathology and pharmacology.

The metabolic syndrome: time for a critical appraisal

R. Kahn, E. Ferrannini, M. Stern, 2005, Diabetologia.

Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes

A. Mari, M. Anselmino, E. Ferrannini, 2011, Diabetologia.